Billing Requirements for Ophthalmic Bevacizumab

As of October 1, 2017, claims for ophthalmic bevacizumab (Avastin®) can no longer be processed when billed using the HCPCS code J3590 (unclassified biologics).

When submitting a claim for the ophthalmic use of bevacizumab, report 1 unit of HCPCS code J9035 (injection, bevacizumab, 10 mg) per eye injected with the appropriate modifier -LT (left eye), -RT (right eye). For bilateral injections, report 1 unit per eye with -LT and -RT modifiers.